Vaxxas Opens World-Class Manufacturing Facility
Monday, June 19, 2023
Vaxxas has announced the opening of its first manufacturing facility in Brisbane, Queensland.
The facility covering an area of 5,500 square metres will support the scale-up of operations for producing HD-MAP vaccines, which will be used in late-stage clinical trials and as the first commercial products.
The new facility aims to increase its manufacturing capacity significantly, leading to the creation of new local jobs that require specialised skills. The expanded capacity will also facilitate the progress of late-stage clinical trials, ultimately allowing to bring the first commercial vaccine products to the market.
The site will significantly increase the manufacturing capacity, creating new local, skilled jobs, while enabling to progress through late-stage clinical trials that will bring the first commercial vaccine products to the market.
One of the key advantages of this new facility is that it enables research and development teams to work closely with manufacturing teams. Additionally, the facility's design and production processes serve as a blueprint for scalable manufacturing, which can be replicated by Vaxxas both domestically and internationally as demand for its platform technology grows.
